Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 128

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 128
---
,814 5 (548)Effect of foreign exchange rates on cash(11)(4)(9)Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents(450)(70)(1,042)Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period1,055 1,126 2,168 Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$606 $1,055 $1,126 

See notes to the consolidated financial statements. Amounts may not foot due to rounding.

70

BOSTON SCIENTIFIC CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS (SUPPLEMENTAL INFORMATION)

Year Ended December 31,(in millions)202420232022Supplemental InformationCash paid for income taxes, net$656 $512 $662 Cash paid for interest250 259 450 Fair value of contingent consideration recorded in purchase accounting29 273 — Non-cash impact of transferred royalty rights(20)(30)(70)(in millions)As of December 31,Reconciliation to amounts within the consolidated balance sheets:202420232022Cash and cash equivalents$414 $865 $928 Restricted cash and restricted cash equivalents included in Other current assets111 130 149 Restricted cash equivalents included in Other long-term assets80 60 48 Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period$606 $1,055 $1,126 

See notes to the consolidated financial statements. Amounts may not foot due to rounding.

71

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

NOTE A – SIGNIFICANT ACCOUNTING POLICIESPrinciples of ConsolidationOur consolidated financial statements include the accounts of Boston Scientific Corporation's wholly owned subsidiaries and entities for which we have a controlling financial interest. All intercompany balances and transactions have been eliminated in consolidation. In the first quarter of 2023, we acquired a majority stake investment in Acotec Scientific Holdings Limited (Acotec) and have elected to consolidate their financial statements on a one quarter lag.When used in this report, the terms "we," "us," "our" and "the Company" mean Boston Scientific Corporation and its divisions and subsidiaries. We assess the terms of our investment interests to determine if any of our investees meet the definition of a variable interest entity (VIE). For